United States Immunotherapy Drugs Market 2033 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Immunotherapy Drugs Market Size reached US$ 288.02 Billion in 2024 and is expected to reach US$ 872.64 Billion by 2033, growing at a CAGR of 13.2% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/immunotherapy-drugs-market?sb

Key Development:

United States: Recent Immunotherapy Drug Developments

✅ In November 2025, the FDA approved Durvalumab (Imfinzi) plus FLOT chemotherapy as neoadjuvant and adjuvant treatment for resectable gastric and gastroesophageal‐junction (GEJ) cancers marking the first immunotherapy regimen for early-stage gastric/GEJ cancers in the U.S.

✅ In October 2025, Cemiplimab (Libtayo) was approved as adjuvant therapy in adults with high-risk cutaneous squamous-cell carcinoma (CSCC) following surgery and radiation, expanding its use to help prevent recurrence in earlier-stage disease.

✅ In October 2025, the FDA expanded the label for Libtayo as an add-on treatment for skin cancer patients with high risk of recurrence a shift toward using immunotherapy in a broader skin-cancer population beyond advanced disease.

✅ In September 2025, the FDA approved a new subcutaneous formulation of Pembrolizumab (Keytruda), offering a faster, more convenient option over traditional IV infusion for cancer patients.

Japan: Recent Immunotherapy Drug Developments

✅ In September 2025, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved several new therapies including immunotherapies, reflecting ongoing regulatory activity in cancer drugs.

✅ In August 2025, Ono Pharmaceutical and Bristol‐Myers Squibb K.K. received supplemental approval in Japan for the combination therapy Nivolumab + Ipilimumab (Opdivo + Yervoy) for unresectable or recurrent MSI‐High colorectal cancer.

✅ In August 2025, Japan approved the combination immunotherapy regimen of Nivolumab + Ipilimumab for advanced MSI‐High colorectal cancer, offering new treatment options for patients with colorectal malignancies unresponsive to conventional chemotherapy.

✅ In August 2025, Japan's approval for Opdivo + Ipilimumab in MSI‐High colorectal cancer reflects adoption of dual checkpoint blockade as a standard therapy for patients with poor-prognosis colorectal cancer.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=immunotherapy-drugs-market

Recent Mergers and acquisitions:

United States:

✅ In November 2025, Johnson & Johnson (J&J) agreed to acquire Halda Therapeutics, a U.S.-based cancer-drug biotech, for about $3.05 billion, boosting J&J's oncology pipeline with Halda's early-stage tumor therapies.

✅ In late October 2025, Takeda Pharmaceutical Company entered a global license and co-development deal with Innovent Biologics (China) to develop two next-generation cancer-immunotherapy/ADC candidates, with global rights outside Greater China a deal worth up to $11.4 billion.

✅ In October 2025, as part of the Takeda-Innovent agreement, Takeda secured an option for a third early-stage investigational program, expanding potential future immuno-oncology assets.

Japan & Asia-region:

✅ In October 2025, Takeda's global collaboration with Innovent Biologics marked one of the largest recent oncology-licensing deals, aimed at bringing late-stage IO/ADC therapies to global markets, significantly strengthening Takeda's immunotherapy and cancer-drug pipeline.

✅ In August 2025, Sun Pharmaceutical Industries completed the acquisition of U.S.-based Checkpoint Therapeutics, which owns the FDA-approved anti-PD-L1 immunotherapy Cosibelimab, extending Sun Pharma's reach in onco-dermatology globally.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/immunotherapy-drugs-market?sb

Key Players:

=> Daiichi Sankyo Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Inc., Amgen, Inc., Merck & Co., Inc., Alligator Bioscience, Bristol-Myers Squibb, Novartis AG, and AstraZeneca and among others.

Key Segments:

By Drug Type

Monoclonal antibodies lead with 35% share, driven by their widespread adoption in oncology, autoimmune disorders, and targeted therapies across hospitals and specialized clinics. Vaccines account for 25%, supported by preventive immunization programs, pandemic preparedness, and increasing adoption in infectious disease management. Interferons alpha and beta hold 10%, reflecting their use in antiviral therapies, multiple sclerosis, and immune modulation. Interleukins and checkpoint inhibitors represent 15%, fueled by immuno-oncology applications and novel therapeutic development. Other drug types make up 15%, including gene therapies, fusion proteins, and emerging biologics addressing niche indications.

By Therapy Area

Oncology dominates with 40% share, driven by rising cancer incidence, advanced treatment options, and adoption of monoclonal antibodies and checkpoint inhibitors. Autoimmune and inflammatory diseases account for 25%, supported by biologics targeting rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Infectious diseases hold 20%, fueled by vaccine adoption and therapeutic biologics for viral and bacterial infections. Other therapy areas make up 15%, including rare diseases, metabolic disorders, and niche therapeutic segments.

By End-User

Hospitals lead with 55% share, reflecting the administration of biologics, monoclonal antibodies, and vaccines in inpatient and specialized treatment settings. Clinics account for 25%, supported by outpatient care, infusion centers, and immunization services. Cancer research centers hold 10%, reflecting clinical trials, experimental therapies, and immunotherapy research. Other end-users make up 10%, including homecare providers, specialty labs, and public health facilities.

By Region

North America - 40% Share
North America leads with 40%, driven by advanced healthcare infrastructure, high R&D investments, early adoption of biologics, and strong presence of pharmaceutical companies in the U.S. and Canada.

Europe - 25% Share
Europe holds 25%, supported by established healthcare systems, biologics adoption, and research-driven therapy development in Germany, France, U.K., Italy, Spain, and neighboring regions.

Asia Pacific - 20% Share
Asia Pacific accounts for 20%, fueled by rising healthcare expenditure, increasing biologics adoption, vaccine programs, and growing disease prevalence in China, India, Japan, and Southeast Asia.

Latin America - 7% Share
Latin America holds 7%, driven by expanding hospital networks, vaccine programs, and biologics adoption in Brazil, Mexico, and surrounding countries.

Middle East & Africa - 8% Share
The Middle East & Africa represent 8%, supported by government healthcare initiatives, growing biologics adoption, and investments in hospital and clinical infrastructure in GCC countries, South Africa, and other emerging markets.

FAQ

What is the current size of the Immunotherapy Drugs Market?

A: In 2024, the Immunotherapy Drugs Market was valued at US$ 288.02 Billion, reflecting its strong industry presence.

Q2: How large is the Immunotherapy Drugs Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Immunotherapy Drugs Market will grow to around US$ 872.64 Billion, demonstrating significant expansion.

Q3: What is the growth rate of the Immunotherapy Drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 13.2% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.